New insider activity at Twist Bioscience ( (TWST) ) has taken place on February 5, 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chief Accounting Officer Robert F. Werner has recently cashed out a portion of his holdings in Twist Bioscience, selling 7,000 shares of company stock in a transaction valued at $319,480. This insider move highlights a notable monetization of equity by a key financial executive at the biotech firm.
Recent Updates on TWST stock
Over the last 24 hours, Twist Bioscience shares have jumped about 12.5% to roughly $46, driven by strong earnings and multiple analyst price target increases. Baird, Evercore ISI, and Barclays all raised their targets after the company reported Q1 results showing double‑digit revenue growth, expanding gross margins around 52%, and a raised fiscal 2026 revenue outlook supported by broad-based momentum across DNA synthesis, protein solutions, and NGS. Analysts cited normalization in NGS demand, robust AI‑driven drug discovery and AI‑enabled discovery orders, and Twist’s growing role as a key tools provider for AI‑based biotech as core reasons for their more optimistic models. They also pointed to evidence of operating leverage, a clearer path to adjusted EBITDA breakeven by 2026, and Twist’s ability to capitalize on an expanding addressable market, despite ongoing losses and elevated investment spending, as justification for revising their assumptions and tightening long‑term growth and profitability expectations upward.
Spark’s Take on TWST Stock
According to Spark, TipRanks’ AI Analyst, TWST is a Neutral.
Score is held back primarily by weak financial performance driven by ongoing losses and negative operating/free cash flow. Offsetting factors include strong technical momentum and a constructive earnings outlook with raised FY2026 guidance and continued margin expansion, while valuation remains challenged due to lack of profitability and no dividend support.
To see Spark’s full report on TWST stock, click here.
More about Twist Bioscience
YTD Price Performance: 51.70%
Average Trading Volume: 1,481,682
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.95B